open access

Vol 88, No 6 (2020)
Review paper
Published online: 2020-11-20
Submitted: 2020-05-26
Accepted: 2020-08-24
Get Citation

The coincidence of diabetes mellitus and asthma, their probable causal relationships and therapeutic opportunities

Marcin Kosmalski, Monika Różycka-Kosmalska, Andrzej Witusik, Tadeusz Pietras
DOI: 10.5603/ARM.a2020.0168
·
Pubmed: 33393652
·
Adv Respir Med 2020;88(6):590-598.

open access

Vol 88, No 6 (2020)
REVIEWS
Published online: 2020-11-20
Submitted: 2020-05-26
Accepted: 2020-08-24

Abstract

Both the epidemiological data and the everyday medical practice demonstrate the coincidence of various types of diabetes mellitus (DM) in patients with asthma. Specific correlations between the risk of DM in pregnancy, asthma and the consequences of these diseases to the mother and her baby are also explored. The discussion concerning, on the one hand, the impact of asthma-related inflammatory condition on the metabolism of carbohydrates, and, on the other, the presence of chronic hyperglycemia and inflammatory markers observed in patients with asthma, is still ongoing. In the case of asthma and type 1 diabetes mellitus (T1DM), a correlation with the dysfunction of the immune system and the genetic background has been suggested, and in the case of type 2 (T2DM), the vital role of obesity and insulin resistance (IR) to promote excessive proinflammatory immune response. The data indicate that both asthma and DM affect mutually their clinical presentations, including the prognostic values and therapeutic possibilities. The ongoing controversy concerning the effective and safe anti-asthma and hypoglycemizing therapy does not allow for a definitive therapeutic consensus in this group of patients, despite the suggested role of metformin and hyperglycemizing effects of glucocorticoids. Therefore, the objective of the presented paper is a review of the knowledge in the field of DM and asthma coincidence, their probable causal relationships and therapeutic opportunities.

Abstract

Both the epidemiological data and the everyday medical practice demonstrate the coincidence of various types of diabetes mellitus (DM) in patients with asthma. Specific correlations between the risk of DM in pregnancy, asthma and the consequences of these diseases to the mother and her baby are also explored. The discussion concerning, on the one hand, the impact of asthma-related inflammatory condition on the metabolism of carbohydrates, and, on the other, the presence of chronic hyperglycemia and inflammatory markers observed in patients with asthma, is still ongoing. In the case of asthma and type 1 diabetes mellitus (T1DM), a correlation with the dysfunction of the immune system and the genetic background has been suggested, and in the case of type 2 (T2DM), the vital role of obesity and insulin resistance (IR) to promote excessive proinflammatory immune response. The data indicate that both asthma and DM affect mutually their clinical presentations, including the prognostic values and therapeutic possibilities. The ongoing controversy concerning the effective and safe anti-asthma and hypoglycemizing therapy does not allow for a definitive therapeutic consensus in this group of patients, despite the suggested role of metformin and hyperglycemizing effects of glucocorticoids. Therefore, the objective of the presented paper is a review of the knowledge in the field of DM and asthma coincidence, their probable causal relationships and therapeutic opportunities.

Get Citation

Keywords

diabetes; asthma; epidemiology; immunopathology; treatment

About this article
Title

The coincidence of diabetes mellitus and asthma, their probable causal relationships and therapeutic opportunities

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 6 (2020)

Article type

Review paper

Pages

590-598

Published online

2020-11-20

DOI

10.5603/ARM.a2020.0168

Pubmed

33393652

Bibliographic record

Adv Respir Med 2020;88(6):590-598.

Keywords

diabetes
asthma
epidemiology
immunopathology
treatment

Authors

Marcin Kosmalski
Monika Różycka-Kosmalska
Andrzej Witusik
Tadeusz Pietras

References (50)
  1. International Diabetes Federation. IDF Diabetes Atlas — 8th Edition. 2017.
  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027): 1513–1530.
  3. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; 12: 204.
  4. Papi A, Brightling C, Pedersen S, et al. Asthma. The Lancet. 2018; 391(10122): 783–800.
  5. Su X, Ren Y, Li M, et al. Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis. Medicine (Baltimore). 2016; 95(22): e3459.
  6. Song Y, Klevak A, Manson JE, et al. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. Diabetes Res Clin Pract. 2010; 90(3): 365–371.
  7. Metsälä J, Lundqvist A, Virta LJ, et al. The association between asthma and type 1 diabetes: a paediatric case-cohort study in Finland, years 1981-2009. Int J Epidemiol. 2018; 47(2): 409–416.
  8. Ma Q, Yang T. [Prevalence and influential factors for asthma among adults in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017; 42(9): 1086–1093.
  9. Hörtenhuber T, Kiess W, Fröhlich-Reiterer E, et al. Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control. Pediatr Diabetes. 2018; 19(4): 727–732.
  10. Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016; 71(4): 339–346.
  11. Fehrenbach H, Wagner C, Wegmann M. Airway remodeling in asthma: what really matters. Cell Tissue Res. 2017; 367(3): 551–569.
  12. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017; 66(2): 241–255.
  13. Agrawal M, Kern PA, Nikolajczyk BS. The immune system in obesity: developing paradigms amidst inconvenient truths. Curr Diab Rep. 2017; 17(10): 87.
  14. Carpio C, Villasante C, Galera R, et al. Systemic inflammation and higher perception of dyspnea mimicking asthma in obese subjects. J Allergy Clin Immunol. 2016; 137(3): 718–26.e4.
  15. Holguin F, Bleecker ER, Busse WW, et al. Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol. 2011; 127(6): 1486–93.e2.
  16. Gomez-Llorente MªA, Romero R, Chueca N, et al. Obesity and asthma: a missing link. Int J Mol Sci. 2017; 18(7).
  17. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6): 1470–1481.
  18. Dandona P, Ghanim H, Monte SV, et al. Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: reduction with weight loss. Obesity (Silver Spring). 2014; 22(2): 356–362.
  19. Sindhu S, Koshy M, Al-Roub AA, et al. Erratum to: 'Differential association of plasma monocyte chemoattractant protein-1 with systemic inflammatory and airway remodeling biomarkers in type-2 diabetic patients with and without asthma'. J Diabetes Metab Disord. 2016; 15: 45.
  20. Vaseghi H, Sanati MH, Jadali Z. T-helper cell type-1 transcription factor t-bet is down-regulated in type 1 diabetes. Iran J Allergy Asthma Immunol. 2016; 15(5): 386–393.
  21. Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016; 4(7): 574–584.
  22. Hekking PP, Amelink M, Wener RR, et al. Comorbidities in difficult-to-control asthma. J Allergy Clin Immunol Pract. 2018; 6(1): 108–113.
  23. Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PLoS One. 2012; 7(5): e36631.
  24. Thuesen BH, Husemoen LLN, Hersoug LG, et al. Insulin resistance as a predictor of incident asthma-like symptoms in adults. Clin Exp Allergy. 2009; 39(5): 700–707.
  25. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43(2): 343–373.
  26. Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70(10): 984–989.
  27. De Santi F, Zoppini G, Locatelli F, et al. Type 2 diabetes is associated with an increased prevalence of respiratory symptoms as compared to the general population. BMC Pulm Med. 2017; 17(1): 101.
  28. Hörtenhuber T, Kiess W, Fröhlich-Reiterer E, et al. Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control. Pediatr Diabetes. 2018; 19(4): 727–732.
  29. Klein OL, Aviles-Santa L, Cai J, et al. Hispanics/Latinos With Type 2 Diabetes Have Functional and Symptomatic Pulmonary Impairment Mirroring Kidney Microangiopathy: Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Diabetes Care. 2016; 39(11): 2051–2057.
  30. Klein OL, Kalhan R, Williams MV, et al. Lung spirometry parameters and diffusion capacity are decreased in patients with Type 2 diabetes. Diabet Med. 2012; 29(2): 212–219.
  31. Stegberg M, Hasselgren M, Montgomery S, et al. Changes in smoking prevalence and cessation support, and factors associated with successful smoking cessation in Swedish patients with asthma and COPD. Eur Clin Respir J. 2018; 5(1): 1421389.
  32. Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017; 39(11): 2216–2229.
  33. Sullivan PW, Ghushchyan VH, Globe G, et al. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018; 141(1): 110–116.e7.
  34. Daugherty J, Lin X, Baxter R, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2018; 55(6): 651–658.
  35. Hamada S, Kuroe A, Tsukino M. Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus? Rev Port Pneumol (2006). 2017; 23(5): 303–304.
  36. Wytrychowski K, Obojski A, Hans-Wytrychowska A. The influence of insulin therapy on the course of acute exacerbation of bronchial asthma. Adv Exp Med Biol. 2016; 884: 45–51.
  37. Ahmadizar F, Souverein PC, Arets HGM, et al. Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. Pediatr Pulmonol. 2016; 51(11): 1113–1121.
  38. American Diabetes Association Standards of Medical Care. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020; 43(Supplement 1): S98–110.
  39. Li CY, Erickson SR, Wu CH. Metformin use and asthma outcomes among patients with concurrent asthma and diabetes. Respirology. 2016; 21(7): 1210–1218.
  40. Vaez H, Najafi M, Toutounchi NS, et al. Metformin alleviates lipopolysaccharide-induced acute lung injury through suppressing toll-like receptor 4 signaling. Iran J Allergy Asthma Immunol. 2016; 15(6): 498–507.
  41. Chen CZ, Hsu CH, Li CY, et al. Insulin use increases risk of asthma but metformin use reduces the risk in patients with diabetes in a Taiwanese population cohort. J Asthma. 2017; 54(10): 1019–1025.
  42. Byelan OV, Borzykh OA, Mamontova TV, et al. Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease. Ter Arkh. 2015; 87(9): 44–51.
  43. Dixon AE, Subramanian M, DeSarno M, et al. A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. Respir Res. 2015; 16: 143.
  44. Anderson JR, Mortimer K, Pang L, et al. Evaluation of the PPAR-γ agonist pioglitazone in mild asthma: a double-blind randomized controlled trial. PLoS One. 2016; 11(8): e0160257.
  45. Colice G, Price D, Gerhardsson de Verdier M, et al. The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. Pragmat Obs Res. 2017; 8: 231–240.
  46. Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018; 142(5): 1515–1528.e8.
  47. Haataja P, Korhonen P, Ojala R, et al. Asthma and atopic dermatitis in children born moderately and late preterm. Eur J Pediatr. 2016; 175(6): 799–808.
  48. Baribeau V, Beauchesne MF, Rey É, et al. The use of asthma controller medications during pregnancy and the risk of gestational diabetes. J Allergy Clin Immunol. 2016; 138(6): 1732–1733.e6.
  49. Zugna D, Galassi C, Annesi-Maesano I, et al. Maternal complications in pregnancy and wheezing in early childhood: a pooled analysis of 14 birth cohorts. Int J Epidemiol. 2015; 44(1): 199–208.
  50. Aspberg S, Dahlquist G, Kahan T, et al. Is neonatal phototherapy associated with an increased risk for hospitalized childhood bronchial asthma? Pediatr Allergy Immunol. 2007; 18(4): 313–319.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl